Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ABL1 | P00519 | 4/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365870 | 0.90 | HTR1F (0.33) | ADORA2AABL1ADORA2BP2RX7HTR1F | |
| SCHEMBL16238775 | 0.83 | ADORA2A (0.33) | ADORA2AABL1ADORA2BP2RX7HTR1F | |
| SCHEMBL16238778 | 0.83 | ADORA2A (0.33) | ADORA2AABL1ADORA2BP2RX7HTR1F | |
| SCHEMBL19670383 | 0.79 | MEN1 (0.36) | — | |
| SCHEMBL19670507 | 0.74 | KARS1 (0.34) | ABL1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19670514 | 0.74 | KARS1 (0.34) | ABL1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL16776202 | 0.73 | DGAT2 (0.34) | ADORA2AABL1ADORA2BHTR1FCACNA1G | |
| SCHEMBL19365507 | 0.69 | MAPT (0.37) | MCHR1 | |
| SCHEMBL19670291 | 0.69 | CACNA1G (0.36) | ADORA2AABL1HTR1FCACNA1GCACNA1H | |
| SCHEMBL19365678 | 0.69 | PDE10A (0.34) | CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ADORA2A 2325/4885ABL1 4089/4885ADORA2B 2412/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | ADORA2A 2325/4885ABL1 4089/4885ADORA2B 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.